GlaxoSmithKline PLC (GSK)
17 Dec 2013
|Market Cap (Mil.):||$125,016.80|
|Shares Outstanding (Mil.):||2,427.66|
Dec 20 - GlaxoSmithKline Plc : * Joint press release: GSK and mmv announce FDA breakthrough therapy designation for Tafenoquine for plasmodium vivax malaria * Tafenoquine is not yet approved or licensed for use anywhere in the world * Plans are underway to start a phase III study in 2014 * For more news, please click here
Dec 20 - GlaxoSmithKline Plc : * GSK Cervarix two-dose schedule receives european marketing authorisation * European commission has granted marketing authorisation for its cervical
LONDON - Denmark has approved the sale of a generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair, threatening future sales of the British firm's biggest product.
* Green light generic copy of GSK's $8-billion drug Advair
Dec 18 - The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's new lung drug for treatment of chronic obstructive pulmonary disease (COPD), commonly known as smoker's lung.
Dec 18 - Oxford BioMedica PLC : * Announces option agreement with GlaxoSmithkline * Grants GSK an option for the development of up to six candidates targeting
LONDON - GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff - a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit. | Video
* Ending sales reps' targets globally following U.S. move
SHANGHAI - Chinese drugmaker Shanghai Pharmaceuticals Holding Co Ltd said it is investigating an allegation in local media that a subsidiary bribed hospital and industry staff to boost drug sales.
SHANGHAI, Dec 17 - Chinese drugmaker Shanghai Pharmaceuticals Holding Co Ltd said it is investigating an allegation in local media that a subsidiary bribed hospital and industry staff to boost drug sales.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥5,020||-50.00|
|The Procter & Gamble Company (PG.N)||$81.84||-0.06|
|Johnson & Johnson (JNJ.N)||$92.09||+0.11|
|Pfizer Inc. (PFE.N)||$30.25||-0.46|
|Novartis AG (NOVN.VX)||CHF70.45||+0.05|
|Unilever N.V. (UNc.AS)||€28.54||+0.23|
|Unilever N.V. (UNIA.AS)||€28.53||+0.07|
|Unilever N.V. (UN_pa.AS)||--||--|
|Unilever N.V. (UN_p.AS)||€75.00||+1.50|
|Unilever N.V. (UN_pb.AS)||--||--|
Earnings vs. Estimates
Analyst Research Reports
Provider: Pechala's Reports
Provider: Thomson Reuters Stock Report
Validea Guru Analysis Report for GSK. Analysis using Validea's interpretation of the published quantitative strategies of well-known Wall Street experts including Peter Lynch, Warren Buffett, Ben Graham and Ken Fisher, among others.
Provider: Ford Investor Services, Inc.
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of GLAXOSMITHKLINE PLC -ADR including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research